5 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 5 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Enrolling by invitation 1, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow SPI-1005: new trials by email Literature Review of SPI-1005 trials Research Report on SPI-1005
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPI-1005 in Adults Receiving Cochlear Implant Ebselen, Placebo - Hearing Loss, Cochlear Trauma | Phase 2 | Recruiting | Sound Pharmaceuticals, Incorporated | 40 | 2026-12-01 | 2026-06-26 |
| SPI-1005 for the Treatment of Meniere's Disease (Open Label) Ebselen - Meniere's Disease, Ménière's Disease | Phase 3 | Active not recruiting | Sound Pharmaceuticals, Incorporated | 200 | 2025-10-29 | 2026-07-13 |
| SPI-1005 for the Treatment of Meniere's Disease Ebselen, Placebo - Meniere Disease, Ménière | Phase 3 | Completed | Sound Pharmaceuticals, Incorporated | 220 | 2022-08-02 | 2026-07-23 |
| SPI-1005 Treatment in Moderate COVID-19 Patients Ebselen, Placebo - Covid19, Corona Virus Infection | Phase 2 | Enrolling by invitation | Sound Pharmaceuticals, Incorporated | 60 | 2021-10-12 | 2023-10-03 |
| SPI-1005 Treatment in Severe COVID-19 Patients Ebselen, Placebo - Covid19, Coronavirus | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 25 | 2021-08-27 | 2026-06-29 |
| IMPase in Treatment-resistant Depression Ebselen, Placebo - Depressive Disorder, Treatment-Resistant | Phase 1 | Unknown | University of Oxford | 50 | 2021-04-22 | 2023-07-06 |
| Ebselen as an add-on Treatment in Hypo/Mania Ebselen, Placebo oral capsule - Bipolar Disorder, Bipolar Disorder, Manic | Phase 2 | Completed | University of Oxford | 60 | 2017-10-01 | 2019-09-06 |
| Study to Evaluate SPI-1005 in Adults With Meniere's Disease SPI-1005 - Meniere's Disease | Phase 1 / Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 40 | 2015-12-01 | 2026-06-29 |
| Study to Evaluate the Safety and Pharmacokinetics of SPI-1005 SPI-1005, Placebo - Hearing Loss, Cancer | Phase 1 | Completed | Sound Pharmaceuticals, Incorporated | 32 | 2006-05-01 | 2016-06-29 |
| Expanded Access Protocol for SPI-1005 Ebselen - Meniere's Disease, Meniere Disease | Temporarily not available | Sound Pharmaceuticals, Incorporated | 2026-10-14 |
Hearing Loss (5) · Meniere Disease (4) · Tinnitus (3) · Vertigo (3) · COVID-19 (2) · Coronavirus Infections (2) · Dizziness (2) · Bipolar Disorder (1) · Depressive Disorder, Treatment-Resistant (1) · Hearing Loss, Sudden (1) · Neoplasms (1)
Sound Pharmaceuticals, Incorporated (8) · University of Oxford (2)
United States (7) · United Kingdom (2)
Miriam Treggiari, MD (2) · Philip J Cowen, MBBS, MD (2) · James C. Kisicki, M.D. (1) · Jonathan Kil, MD (1)
2015 (1)